Among all of the cathecolamines used for cardiac arrest treatment, epi
nephrine injection during cardio-pulmonary resuscitation is currently
the most powerful means of enhancing effectiveness; however, deliberat
ions about the optimal dosage have recently become intense. In the SAM
U of Lyon (F), we conducted a double blind prospective randomized stud
y over an 18-month period, comparing repeated standard-dose epinephrin
e (1 mg) and repeated high-dose epinephrine (5 mg) in the management o
f cardiac arrest outside the hospital. Five-hundred thirty-six patient
s were enrolled with 265 in the standard-dose group and 271 in the hig
h-dose group; both groups are globally similar. One-hundred eighty-one
(33.8%) patients returned to spontaneous circulation (R.O.S.C.); 85 i
n the standard-dose group (32%) and 96 in the high-dose group (35.5%).
One-hundred nineteen patients (22.2%) were admitted; 54 in the standa
rd-dose group (20.4%) and 65 in the high-dose group (24%). At 6 months
nine patients (7.6%) were alive; three patients from the standard-dos
e group (5.5%) and six from the high-dose group (9.2%). We never notic
ed cardiac or neurologic adverse effects with the high doses. The resu
lts of this study are not statistically significant, but we observed a
marginal trend towards repeated 5 mg epinephrine doses. A large Frenc
h multicentre study is now necessary.